Last reviewed · How we verify
Trivalent influenza vaccine B
Trivalent influenza vaccine B is a Inactivated influenza vaccine Biologic drug developed by Shanghai Institute Of Biological Products. It is currently in Phase 3 development for Seasonal influenza prevention in adults and children.
This trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain).
This trivalent influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus (typically two A strains and one B strain). Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Trivalent influenza vaccine B |
|---|---|
| Sponsor | Shanghai Institute Of Biological Products |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or attenuated influenza virus antigens that trigger both humoral and cellular immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize circulating influenza viruses, while T cells provide additional immune memory. This prevents infection or reduces disease severity when vaccinated individuals encounter wild-type influenza.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (PHASE3)
- Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine (PHASE2, PHASE3)
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders (PHASE4)
- Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent influenza vaccine B CI brief — competitive landscape report
- Trivalent influenza vaccine B updates RSS · CI watch RSS
- Shanghai Institute Of Biological Products portfolio CI
Frequently asked questions about Trivalent influenza vaccine B
What is Trivalent influenza vaccine B?
How does Trivalent influenza vaccine B work?
What is Trivalent influenza vaccine B used for?
Who makes Trivalent influenza vaccine B?
What drug class is Trivalent influenza vaccine B in?
What development phase is Trivalent influenza vaccine B in?
What are the side effects of Trivalent influenza vaccine B?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Shanghai Institute Of Biological Products — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Compare: Trivalent influenza vaccine B vs similar drugs
- Pricing: Trivalent influenza vaccine B cost, discount & access